Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raludotatug Deruxtecan (R-DXd) in Advanced Ovarian Cancer
NCT07743164Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Primary completion
- Aug 2031
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing R-DXd +/- Bevacizumab with Standard of Care (2 arms). Primary endpoints: Progression-free Survival at 3 years and Overall Survival at 4 years. Started Oct 2026; status: recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT07743164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743164.